PKCβ regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1

Hisaaki Shinohara,1 Tomoharu Yasuda,1 Yuichi Aiba,1 Hideki Sanjo,1 Megumi Hamadate,1 Hiroshi Watarai,2 Hiroaki Sakurai,3 and Tomohiro Kurosaki1

The B cell antigen receptor (BCR)–mediated activation of IκB kinase (IKK) and nuclear factor–κB require protein kinase C (PKC)β; however, the mechanism by which PKCβ regulates IKK is unclear. Here, we demonstrate that another protein kinase, TGFβ-activated kinase (TAK)1, interacts with the phosphorylated CARMA1 (also known as caspase recruitment domain [CARD]11, Bimp3) and this interaction is mediated by PKCβ. IKK is also recruited to the CARMA1–Bcl10–mucosal-associated lymphoid tissue 1 adaptor complex in a PKCβ–dependent manner. Hence, our data suggest that phosphorylation of CARMA1, mediated by PKCβ, brings two key protein kinases, TAK1 and IKK, into close proximity, thereby allowing TAK1 to phosphorylate IKK.

The online version of this article contains supplemental material.

Supplemental Material can be found at: /content/suppl/2005/11/22/jem.20051591.DC1.html

The Journal of Experimental Medicine


© The Rockefeller University Press $8.00
Although adaptor proteins that participate in BCR-mediated IKK activation have been intensively identified, it remains unclear whether the PKCβ and CARMA1–Bcl10–MALT1 complex connect and how, if any, these connections lead to IKK activation. Here, we report that BCR-induced phosphorylation of CARMA1, mediated by PKCβ, contributes to bringing two key protein kinases, TAK1 and IKK, into close proximity. As a result, TAK1 is able to function as an upstream kinase for IKK activation in BCR signaling context.

RESULTS
TAK1 is required for BCR-mediated IKK activation
Given the previous evidence that BCR-mediated IKK activation is impaired in protein kinase C (PKC)β- or CARMA1-deficient primary B cells (10, 11, 21–24), we examined whether requirement for these molecules is recapitulated in DT40 B cells. For this purpose, we established PKCβ- or CARMA1-deficient cells. As shown in Fig. 1, both of these deficient DT40 cells failed to activate IKK and degrade IκBα upon BCR engagement. The defective NF-κB activation in PKCβ- or CARMA1–deficient DT40 cells was not due to the decreased BCR expression (Fig. S1 B, available at http://www.jem.org/cgi/content/full/jem.20051591/DC1). These observations allowed us to choose the chicken DT40 B cell system for elucidating the molecular connections between PKCβ and IKK in BCR signaling.

![Figure 1](image)

Figure 1. PKCβ and CARMA1 are essential for IKK activation in DT40 cells. BCR-mediated IKK activation in DT40 wild-type (wt), PKCβ- (PKCβ−/−), and CARMA1-deficient (CARMA1−/−) DT40 B cells. For IKK activation, 10⁷ cells/lane were subjected to IKK kinase assay. IKK kinase activity was measured by phosphorylation of GST-IκBα as a substrate and detected by anti-phospho-IκBα mAb (top). IκBα degradation was analyzed by Western blotting with anti-IκBα Ab (middle). NF-κB activity was examined by EMSA (bottom). Position of the NF-κB complex is indicated by arrow.

Normal PKCβ activation in the absence of TAK1
As demonstrated before, TAK1-deficient DT40 B cells manifested the similar defect in BCR-mediated IKK activation to that in PKCβ- and CARMA1-deficient B cells, suggesting the functional interaction between TAK1 and PKCβ/CARMA1. Thus, to elucidate the mechanism by which TAK1 participates in BCR-mediated IKK activation, we first examined the effects of deletion of TAK1 on PKCβ and CARMA1. As for its effect...
on PKCβ, the activation status of PKCβ was, as judged by using anti–phospho-PKCβ Ab, not affected in TAK1-deficient DT40 B cell (Fig. 3 A). Thus, PKCβ likely lies upstream of TAK1, thereby contributing to BCR-mediated IKK activation. As a readout of CARMA1 action, we considered the possibility that CARMA1 might undergo serine/threonine phosphorylation upon BCR engagement because a physical interaction between CARMA1 and PKCβ was reported in nonlymphoid cells (40). Indeed, CARMA1 underwent phosphorylation, as determined by anti–phospho-serine/threonine Ab by BCR cross-linking in DT40 B cells. This CARMA1 phosphorylation occurred even in TAK1-deficient cells, but the extent was decreased by ~20% at 3 min after stimulation when compared with wild-type cells (Fig. 3 B).

In the absence of PKCβ or CARMA1, TAK1 activation, judged by anti–phospho-serine/threonine blotting, was greatly decreased, compared with wild-type DT40 B cells (Fig. 3 C). These observations suggest that PKCβ- and CARMA1-mediated events augment TAK1 activity during BCR signaling.

Interaction of TAK1 with CARMA1

To further address the mechanism by which TAK1 leads to the activation of IKK, we analyzed whether TAK1 interacts with PKCβ and/or CARMA1 in DT40 B cells that are unstimulated or stimulated. Efficient interaction between TAK1 and CARMA1 was observed in stimulated B cells (Fig. 4 A). This inducible association was also observed in...
primary B cells after BCR stimulation (Fig. 4 B). Although fivefold higher amount of TAK1 was immunoprecipitated, we could not detect reproducible association of TAK1 with PKCζ (unpublished data). To assess the functional importance of this association, we made TAK1 mutants and examined their functions. The COOH-terminal region of TAK1 (402–579 amino acids) is thought to bind to a TAK1-binding protein, TAB2, in the IL-1 signaling pathway (41). In contrast with the dB mutant, the dA mutant failed to associate with CARMA1 upon BCR engagement and to activate IKK (Fig. 5, A–C). This failure was not due to its defective kinase activity because the immunoprecipitated dA TAK1 mutant, once overexpressed in 293T cells, exhibited the similar kinase activity to that of wild-type (Fig. 5 D). Therefore, we conclude that after BCR stimulation, TAK1 is recruited to CARMA1 directly or indirectly, which in turn contributes to subsequent IKK activation.

**Interaction of TAK1 with CARMA1 is dependent on PKCζ**

Having demonstrated the necessity of interaction between TAK1 and CARMA1 in BCR-mediated IKK activation, next we determined how this association is formed. As CARMA1 was phosphorylated by BCR stimulation, we reasoned that BCR-induced interaction between TAK1 and CARMA1 might be associated with CARMA1 phosphorylation status. As shown before, phosphorylation of CARMA1 at 3 min after BCR stimulation occurred in TAK-deficient DT40 B cells. Thus, we considered PKCζ as a key kinase for initiating phosphorylation of CARMA1 after BCR stimulation. In the absence of PKCζ, the phosphorylation of CARMA1 was not induced by BCR ligation (Fig. 6 A). Importantly, BCR-mediated interaction between TAK1 and CARMA1 was also greatly reduced in PKCζ-deficient DT40 B cells. Thus, at 3 min after BCR stimulation, the CARMA1 phosphorylation status appeared to be well correlated with the interaction status between TAK1 with CARMA1 (Fig. 6, A and B). Moreover, comparison of wild-type and PKCζ-deficient DT40 B cells indicated that inducible association of CARMA1 with Bcl10 and MALT1 was also well correlated with the phosphorylation status of CARMA1 at 3 min after receptor ligation (Fig. 6 C). Together, these observations suggest that the initial phase of CARMA1 phosphorylation could contribute to its inducible association with TAK1 and Bcl10.

Although CARMA1 phosphorylation, judged by anti–phospho-serine/threonine Ab, continued 10 min after BCR ligation, its association with TAK1 and Bcl10 was decreased to an almost resting level (Fig. 6, A–C). Assuming that CARMA1 undergoes phosphorylation on multiple serine and threonine residues upon BCR stimulation, one of the straightforward explanations for these observations is that the initial phosphorylation sites could contribute to association...
of CARMA1 with TAK1 and Bcl10, whereas the sites, being phosphorylated in the later phase (10 min after stimulation), could play a negative role in its association.

**TAK1 is able to phosphorylate IKK**

Given the importance of the CARMA1–Bcl10–MALT1 complex in IKK activation, the aforementioned data suggest that TAK1, when interacted with the phosphorylated CARMA1, gains access to its substrate IKK, which in turn transphosphorylates conserved serines located within the activation loop of IKKβ/IKKα. Hence, to test this hypothesis, we examined whether IKK is associated with CARMA1 after BCR cross-linking and, if so, whether this association is dependent on PKCβ.

We also tested whether TAK1 is able to phosphorylate IKKβ. For this purpose, transfected Flag-tagged TAK1 and its kinase-defective mutant were immunoprecipitated from stimulated DT40 B cells, and incubated with recombinant glutathione S-transferase (GST)-IKKβ as a substrate. As demonstrated in Fig. 7 A, only wild-type TAK1 led to strong phosphorylation of recombinant GST-IKKβ after

---

**Figure 5. Requirement for interaction between TAK1 and CARMA1 in NF-κB activation.**

(A) Schematic diagram of various TAK1 mutant constructs. (B) Interaction of various mutant TAK1 with CARMA1. TAK1 mutants were transfected into TAK1-deficient DT40 cells. Cell lysates (2 × 10^7 cells/sample) were immunoprecipitated by anti-Flag mAb, followed by Western blotting using anti-CARMA1 Ab. (C) Detection of IκBα degradation was performed as in Fig. 1. (D) For detection of potentiality of these mutant TAK1 kinase activity, each construct shown in A was transiently transfected with TAB1 into 293T cells. Cells were lysed and immunoprecipitated by anti-Flag mAb. The immunocomplexes were subjected to kinase assay using GST-IKKβ as a substrate. In lane 1 (asterisk), GST-IKKβ in which S177 and S181 were mutated to A177 and A181 was used as a negative control substrate.

**Figure 6. Interaction of TAK1 with CARMA1 is dependent on PKCβ.**

(A) For phosphorylation of CARMA1 in wild-type or PKCβ−/− DT40 cells, immunoprecipitation and Western blotting were performed as Fig. 3 B. (B) For association of TAK1 and CARMA1, cell lysates from TAK1- or PKCβ-deficient DT40 cells, both of which expressed Flag-tagged wild-type TAK1, were immunoprecipitated with anti-Flag mAb and analyzed by Western blotting using anti-CARMA1 Ab. (C) For interaction of CARMA1 with Bcl10 or MALT1 in PKCβ−/− cells, cytosolic extracts from 4 × 10^7 cells per sample were immunoprecipitated with anti-CARMA1 Ab and analyzed by Western blotting using anti-Bcl10 or -MALT1 Abs.
stimulation. As a further negative control, we also used a recombinant GST-IKK\nmutant in which two conserved serine residues (S177 and S181) in the activation loop of IKK\nwere changed to alanine residues (Fig. 7 B, lane 4), demonstrating that these sites are indeed phosphorylated by immunoprecipitated TAK1. The aforementioned data raised the possibility that either TAK1, or a kinase that may associate with the TAK1 immunocomplex, is one of the IKK kinases.

**DISCUSSION**

Despite the importance of PKCβ in BCR-induced IKK activation, the underlying mechanism has remained unclear. In this study, we provide several lines of evidence in support of the critical role of PKCβ-mediated phosphorylation of CARMA1 in bringing two key enzymes TAK1 and IKK into close proximity with each other, thereby activating IKK by BCR stimulation. A model for the mechanism of PKCβ-mediated activation of IKK during BCR signaling, based on the data presented here, is shown in Fig. 8. Involvement of PKCβ in BCR–mediated CARMA1 phosphorylation is clear; however, our data has not addressed the issue of whether PKCβ phosphorylates CARMA1 after BCR stimulation, directly or indirectly. In this regard, as in T cells, PDK1 might facilitate the functional interaction between PKCβ and CARMA1 in B cells (42).

The initial phosphorylation of CARMA1 (3 min after stimulation) mediated by PKCβ is most likely to cause its association with TAK1 and Bcl10/MALT1 complex, which is supported by two lines of our observations. First, the comparison between wild-type and PKCβ-deficient DT40 cells clearly showed the well correlation between the inducible phosphorylation status of CARMA1 and its association with TAK1, Bcl10, and MALT1 at 3 min after BCR stimulation (Fig. 6). Second, BCR–mediated phosphorylation of CARMA1 still occurred in TAK1-deficient DT40 cells (Fig. 3 B), implying that the initial CARMA1 phosphorylation precedes its association with TAK1 during BCR signaling.

Next, the question of how CARMA1 phosphorylation contributes to its association with Bcl10 and TAK1 arises. CARMA1 contains a set of motifs (PDZ, SH3, and GUK domains) that define MAGUK family proteins (29, 43). The best characterized member of this family, PSD-95, forms relatively stable, detergent-resistant, and microfilament-independent multiprotein aggregations at postsynaptic membrane densities in neurons (44, 45). Furthermore, it has been proposed that the intramolecular interactions of PSD-95, such as between the SH3 and GUK domains, keep it in a closed, inactive conformation, whereas binding to a regulatory ligand could induce an opening of the conformation that would allow for subsequent intermolecular SH3–GUK interactions and dimerization or multimerization. In addition to MAGUK-typical features, CARMA1 contains two additional protein–protein interaction domains; a CARD domain and a coiled-coil domain. The CARD domain of CARMA1 is shown to mediate binding to Bcl10, whereas its coiled-coil domain is thought to mediate homo- and/or hetero-multimerization (23, 28, 32). Thus, it is reasonable to anticipate that the initial phosphorylation of CARMA1 (3 min after stimulation), like the regulatory ligand, could in-

---

**Figure 7.** TAK1 is able to phosphorylate IKK. (A) For IKK recruitment to CARMA1, 2 × 10⁶ cell lysates were immunoprecipitated by anti-IKKγ mAb and analyzed by Western blotting using anti-CARMA1 Ab. (B) Cell lysates from the transfectants, as seen in Fig. 2 D, were immunoprecipitated by anti-Flag mAb and performed in vitro kinase assay using GST-IKKβ as a substrate. In the lane 4 (asterisk), GST-IKKβ in which S177 and S181 were mutated to A177 and A181 was used as a negative control substrate.

**Figure 8.** A model for BCR-mediated NF-κB activation. Stimulation of BCR leads to activation of proximal protein tyrosine kinases including Syk and Btk. Btk phosphorylates several tyrosine residues on phospholipase C-γ2 (PLC-γ2), and subsequent activation of protein kinase Cβ (PKCβ). Activated PKCβ phosphorylates CARMA1 (1), directly or indirectly, which is able to recruit TAK1 to the phosphorylated CARMA1 (2). Meanwhile, the IKK complex probably through the Bcl10/MALT1 complex is recruited to the phosphorylated CARMA1 (3 and 4). These interactions (CARMA1-IKK and CARMA1-TAK1) contribute to access of two key protein kinases, TAK1 and IKK, leading to activation of the IKK complex (5).
duce the opening state from its closed conformation, thereby allowing CARMA1 to form homo-oligomerization and hetero-oligomerization with signaling molecules, including Bcl10 and TAK1. However, disparity between phosphorylation status of CARMA1 and its association with Bcl10 and TAK1 (10 min after stimulation) was also observed. These data suggest that CARMA1 might undergo phosphorylation on several serine/threonine residues with distinct time kinetics during BCR signaling and that the sites being phosphorylated with later time kinetics could contribute to terminating these associations.

Although endogenous Bcl10 and MALT1 can be immunoprecipitated from lysates of nonstimulated B and T cells, the physical association of Bcl10 and MALT1 is not clear (31). In the case of DT40 B cells, we observed that this association was inducible (unpublished data). Given that Bcl10 undergoes phosphorylation in antigen receptor signaling (46, 47), this phosphorylation might contribute to further association of Bcl10 and MALT1, thereby making a stable CARMA1–Bcl10–MALT1 complex upon BCR engagement. IKK\(\gamma\) was recruited to CARMA1 after receptor ligation (Fig. 7 A). Thus, the IKK complex including IKK\(\gamma\) might be directly associated with CARMA1–Bcl10–MALT. It is also possible that TRAF6 and/or ECSIT (evolutionarily conserved signaling intermediate in toll pathways) might function as a connecting molecule between CARMA1–Bcl10–MALT1 and the IKK complex (33, 34, 48).

Importance of phosphorylation of the activation loop serine residues of IKK\(\alpha\) and IKK\(\beta\) has been demonstrated in vivo as well as in vitro experiments (37, 49, 50). As these serine residues are not part of a PKC consensus phosphorylation site, two mechanistic ideas have been proposed. First, other serine/threonine residues of IKK\(\alpha\) and IKK\(\beta\) may serve as direct substrates of PKC\(\beta\), thereby contributing to IKK activation. Alternatively, PKC\(\beta\) may regulate IKK indirectly through an intermediate kinase that would be directly or indirectly controlled by PKC\(\beta\). Although the first possibility cannot be completely excluded, our data highly suggest that the second mechanism mainly operates in the BCR signaling context and that TAK1 corresponds to this intermediate kinase. First, consistent with a previous report using Jurkat T cells (34), TAK1 was demonstrated to play a critical role in BCR–mediated IKK activation in DT40 B cells. Second, because PKC\(\beta\) activation occurred normally in the absence of TAK1, TAK1 is likely activated downstream of PKC\(\beta\). Third, immunoprecipitated TAK1, but not its kinase mutant, was able to phosphorylate activation loop serine residues of IKK\(\beta\) in in vitro conditions.

In contrast with wild-type DT40 cells, TAK1 activation status, as judged by antiphospho-serine/threonine Ab, was greatly decreased in both PKC\(\beta\)- and CARMA1-deficient cells, suggesting involvement of PKC\(\beta\)-mediated CARMA1 phosphorylation and probably subsequent association of CARMA1 and TAK1 in its activation. In this regard, the dA TAK1 mutant is thought to be devoid of a binding site to TAB2, an adaptor molecule linking TRAF6 and TAK1 in IL-1 receptor signaling (41). Thus, TAB2 could be one of the candidates that contribute to association of CARMA1 with TAK1. In addition to TAK1 activation, substrate accessibility is important. Association of both TAK1 and IKK complex with CARMA1 and dependency of these associations on PKC\(\beta\) were clearly demonstrated by this study. Hence, these associations likely allow the activated TAK1 to phosphorylate IKK\(\beta\) in in vivo contexts. Furthermore, because MALT1 is reported to activate IKK by promoting the ubiquitination of the IKK\(\gamma\) directly, or indirectly through TRAF6 (33–35), this IKK\(\gamma\) ubiquitination may contribute to bringing IKK\(\beta\) into a state that is more susceptible to being phosphorylated by TAK1.

TAK1 was reported as a kinase coupling innate receptors, Toll-like receptors/IL-1 receptors, to IKK activation (12–17). Therefore, involvement of this kinase also in antigen receptor–mediated IKK activation in DT40 cells has enabled us to provide an insight into how TAK1 participates in adaptive immune receptor signaling such as through BCR. Phosphorylation of a specific scaffold molecule, CARMA1, recruits actions of two common NF-\(\kappa\)B players, TAK1 and IKK, into the adaptive immune receptor signaling. Thus, the adaptive immune system in vertebrates may have evolved from the more primitive innate immune system through usurping the common key signaling components of the NF-\(\kappa\)B pathway, including TAK1 and IKK, by using CARMA1–Bcl10–MALT1.

**MATERIALS AND METHODS**

**Cells, mice, Abs, and reagents.** Wild-type and various mutant DT40 cells were cultured in RPMI 1640 (GIBCO BRL and Invitrogen) supplemented with 10% FCS, 1% chicken serum, 50 \(\mu\)M 2-ME (Sigma-Aldrich), 4 mM L-glutamine, and antibiotics. Wild-type C57BL/6J mice were purchased from Clea Japan. Anti–CARMA1 Ab and anti–I\(\kappa\)B\(\alpha\) Ab were obtained by immunizing rabbits with synthetic peptide (CLQFVSVRSENKYKRMN-SNERVRI) and with bacterially expressed GST fusion proteins containing amino acid sequences coding chicken I\(\kappa\)B\(\alpha\) amino acids 1–103, respectively. Anti–chicken IgM mAb, M4 (51), was used for stimulation of BCR and FACS analysis. Anti–ERK Ab, anti–JNK Ab, anti–TAK1 mAb (C9), anti–Bcl10 mAb (331.3), and anti–MALT1 Ab were purchased from Santa Cruz Biotechnology, Inc. Anti–phospho-PKC\(\beta\) (amino acids 1–103), respectively. Anti–phospho-IKK\(\gamma\) mAb (5A5), anti–phospho-IKK\(\beta\) (amino acids 1–103), respectively. Anti–phospho-serine/threonine Ab were used as anti–phospho-serine/threonine Ab. Anti–FLAG mAb (M2) was obtained from Sigma-Aldrich.

**Expression constructs and transfection.** Flag-tagged mouse wild-type TAK1 and its mutant cDNAs were generated by PCR. Each cDNA was cloned into the pApuro with IRES-GFP expression vector (52). Kinase-dead TAK1, dA TAK1, and dB TAK1 harboured K63W point mutation, internal deletion (amino acids 401–530), and COOH-terminal deletion (amino acids 531–579), respectively. These constructs were transfected into each mutant DT40 cells by electroporation as described elsewhere (51).

**Generation of various deficient DT40 cells.** Based on published sequence of murine PKC\(\beta\)II, CARMA1, and TAK1, we searched each
chicken homologue using the expressed sequence tag database and obtained each chicken cDNA by RT-PCR with RNA from DT40 B cells. Genomic clones of PKCβII, CARMA1, and TAK1 were obtained by PCR using oligonucleotides (designed from each cDNA sequence) and genomic DNA as a template. The targeting vector, pPKCβII-neo or pPKCβII-hisD, was constructed by replacing the genomic fragment containing exons that correspond to murine PKCβII ATP-binding domain with neo or hisD cassette. The targeting constructs for CARMA1 were designed for neo and hisD cassettes to replace the genomic fragment of chicken CARMA1 exons 2–7. The targeting constructs for TAK1 were designed for neo and hisD cassettes to replace the genomic fragment corresponding to murine TAK1 ATP-binding domain. These targeting vectors were sequentially transfected into DT40 cells, resulting in generation of PKCβII-, CARMA1-, or TAK1-deficient DT40 cells, as described previously (51).

Immunoprecipitation and Western blot analysis. For immunoprecipitation, cells were solubilized in NP-40 lysis buffer supplemented with protease and phosphatase inhibitors as described previously (51) and precleared lysates were incubated with proper Abs and protein G-sepharose (GE Healthcare). For Western blot analysis, immunoprecipitates or cleared-cell lysates were resolved on SDS-PAGE, transferred to polyvinylidifluoride (PVDF) membrane (Bio-Rad Laboratories), and incubation with secondary horseradish peroxidase–labeled Ab. The blots were washed and visualized with the SuperSignal West Dura Extended Duration Substrate (Pierce Chemical Co.) or BCIP/NBT Color Development system (Promega).

Electrophoretic mobility shift assay (EMSA). DNA-binding activity of NF-κB was analyzed by EMSA as described previously (52). In brief, the nuclear extracts of DT40 cells (2 × 10^6) treated with 10 μg/ml M4 were purified, incubated with a specific probe for the NF-κB DNA-binding activity (Santa Cruz Biotechnology, Inc.) Abs. The blots were washed and visualized with the SuperSignal West Dura Extended Duration Substrate (Pierce Chemical Co.) or BCIP/NBT Color Development system (Promega).

Electrophoretic mobility shift assay (EMSA). DNA-binding activity of NF-κB was analyzed by EMSA as described previously (52). In brief, the nuclear extracts of DT40 cells (2 × 10^6) treated with 10 μg/ml M4 were purified, incubated with a specific probe for the NF-κB DNA-binding site (5′-CAACGCACGGAGTATCCCCCTTCCCTTCT-3′), electrophoresed, and visualized by autoradiography.

In vitro kinase assay. For IKK and TAK1 kinase assays, 2 × 10^7 DT40 cells stimulated with 10 μg/ml M4 were lysed in 1% NP-40 lysis buffer. Precleared lysates were immunoprecipitated with 1 μg anti-IKKα Ab or 1 μg anti-Flag mAb, followed by incubating with 40 μl of protein G-sepharose. The beads were washed three times with lysis buffer and two times with kinase buffer (25 mM Tris, pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na_2VO_4, 10 mM MgCl_2). Immunoprecipitates were resuspended in kinase buffer containing 100 μM ATP. GST-IκBα (NH₂-terminal of mouse IκBα; amino acids 1–72) or GST-IKKβ (activation loop of human IKKβ; DLGYAKELDQGSLCTSFGVTQLYLAPELLEQQ) or its mutant; DLGY-AKELDQGALCTAFAVGTQLQLAPPELLEQQ) fusion protein (0.2 μg each) was added as a substrate for IKK or TAK1, respectively. After 30 min incubation at 30°C, the reaction was terminated by addition of SDS sample buffer followed by boiling for 5 min. The samples were separated by SDS-PAGE gel, transferred to PVDF membrane, and detected by anti-phospho-IκBα mAb or anti-phospho-IKKα/β Ab, respectively. For JNK kinase assay, JNK kinase assay kit (Cell Signaling Technology Inc.) was used according to the manufacturer’s instructions.

Flow cytometric analysis. Cell surface expression of BCR on various mutant DT40 cells was analyzed by FACSCalibur (Becton Dickinson) using anti–chicken IgM Ab (Bethyl) conjugated with allophycocyanin (Dojindo).

Online supplemental material. Fig. S1 A shows protein expression in DT40 wild-type, TAK1-, PKCβII-, and CARMA1-deficient DT40 B cells analyzed by Western blot. Fig. S1 (B and C) depicts cell surface expression of BCR on various mutant DT40 cells. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20051591/DC1.

We would like to thank our colleagues M. Kurosaki for expert technical assistance and M. Hikida for helpful advice.

This work was supported by grants to T. Kurosaki from the Ministry of Education, Science, Sports, and Culture in Japan and from Takeda Science Foundation. The authors have no conflicting financial interests.

Submitted: 5 August 2005
Accepted: 13 September 2005

REFERENCES


pkcb, tak1, and carma1 in bcr signaling | shinohara et al.


